检索结果 - Cristina Encinas Rodriguez

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

    Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refrac... 由 Noffar Bar, María‐Victoria Mateos, Paz Ribas, Markus Hansson, Laura París, Craig C. Hofmeister, Paula Rodríguez‐Otero, Maria Aranzazu Bermúdez, Thomas G Martin, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas Rodriguez, Claudio Cerchione, Javier de la Rubia, Albert Oriol, Heidi Waibel, Britta Besemer, Ethan Thompson, Brian F. Kiesel, Jinjie Chen, Alexander Yaw Fui Chung, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús F. San Miguel, Luciano J. Costa

    出版 2023
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: